Suggested remit: To appraise the clinical and cost effectiveness of zanubrutinib within its marketing authorisation for treating relapsed or refractory marginal zone lymphoma.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 5085

Provisional Schedule

Expected publication 17 July 2024

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group Newcastle NIHR TAR Team, Newcastle University


Companies sponsors BeiGene (zanubrutinib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Blood Cancer UK
  Lymphoma Action
Professional groups Association of Cancer Physicians
  British Society for Haematology
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Associated public health groups None
Comparator companies Aspen Pharma (chlorambucil) (confidentiality agreement not signed, not participating)
  Baxter Healthcare (cyclophosphamide, doxorubicin) (confidentiality agreement not signed, not participating)
  Celltrion Healthcare (rituximab) (confidentiality agreement not signed, not participating)
  Dr Reddy’s Laboratories (bendamustine) (confidentiality agreement not signed, not participating)
  Hospira (vincristine sulfate) (confidentiality agreement not signed, not participating)
  Medac GmBH (doxorubicin) (confidentiality agreement not signed, not participating)
  Pfizer (doxorubicin, rituximab) (confidentiality agreement not signed, not participating)
  Roche (rituximab) (confidentiality agreement not signed, not participating)
  Sandoz Ltd (cyclophosphamide, rituximab) (confidentiality agreement not signed, not participating)
  Seacross Pharmaceuticals (bendamustine, doxorubicin) (confidentiality agreement not signed, not participating)
  Zentiva (bendamustine) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
07 May 2024 Committee meeting
26 September 2023 Invitation to participate
26 July 2023 - 23 August 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 5085
26 July 2023 In progress. Scoping commencing
22 May 2023 Please note that following on from an update received from the company, the appraisal has been scheduled back into the work programme. Therefore, we now anticipate that the appraisal will begin during late September 2023 when we will write to stakeholders about how they can get involved. The deadline for submissions is expected in approximately late November 2023.
05 October 2022 Suspended. Following on from information received from the company regarding the availability of evidence for this indication, NICE has decided to suspend this appraisal from its current work programme. NICE will continue to monitor any developments and will update interested parties as and when the situation changes.
23 February 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual